<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296281</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F647-1401</org_study_id>
    <nct_id>NCT02296281</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GNI-EPS Pharmaceuticals, Inc. (GNI Group)</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of pirfenidone capsules to
      treat grade 2 or above radiation-induced lung injury patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in radiation-induced lung injury classification</measure>
    <time_frame>36 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Radiation Pneumonitis</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-70 years old (include 18 and 70 years), male or female

          2. The pathological diagnosis of lung cancer, with non-small cell lung cancer (NSCLC)
             staging IIIA or IIIB, and small cell lung cancer (SCLC) in council deadline

          3. General condition assessment, ECOG score of 0-1

          4. Enough heart, liver and kidney function, such as AST, ALT, LDH≤2 times ULN such as
             plasma total bilirubin, creatinine ≤1.5 times ULN; hematopoietic function enough, such
             as neutrophils ≥4.0 x109 / L, platelets ≥100 x109 / L

          5. The expected survival at 6 months or more

          6. Subject is able to eat solid food

          7. The initial radical thoracic radiotherapy treatment

          8. The clinical diagnosis of radiation-induced lung injury in Grade 2 or above

          9. The duration of radiation-induced lung injury in less than 1 month

         10. Signed informed consent

        Exclusion Criteria:

          1. Radiation-induced lung injury has entered the chronic phase

          2. A history of chronic bronchitis, emphysema, or a history of cor pulmonale

          3. Lung resection surgery

          4. Cancer progression

          5. Pulmonary infection

          6. Associated with other serious diseases: such as occurred within 6 months of myocardial
             infarction, uncontrolled diabetes etc.

          7. With active peptic ulcer

          8. Pregnant women and patients with mental disease

          9. Those who participate in clinical trials of other drugs within 3 months

         10. Investigator judge does not apply to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Radiation Pneumonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

